PCRX Pacira BioSciences Inc.

38.22
-0.72  -2%
Previous Close 38.94
Open 39
Price To Book 4.66
Market Cap 1,591,293,484
Shares 41,635,099
Volume 539,953
Short Ratio
Av. Daily Volume 536,091

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved October 31, 2011.
EXPAREL
Postsurgical pain
Approval announced April 6, 2018.
EXPAREL
Post surgical pain

Latest News

  1. Pacira Biosciences Inc (PCRX) CEO and Chairman David M Stack Sold $503,038 of Shares
  2. Pacira (PCRX) Q2 Earnings and Revenues Surpass Estimates
  3. Pacira Pharmaceuticals, Inc. (PCRX) Q2 2019 Earnings Call Transcript
  4. Pacira (PCRX) Beats Q2 Earnings and Revenue Estimates
  5. Pacira BioSciences Reports Second Quarter 2019 Financial Results and Business Update
  6. Pacira BioSciences to Present at the 2019 Wedbush Pacgrow Healthcare Conference
  7. Pacira (PCRX) Earnings Expected to Grow: Should You Buy?
  8. Should You Be Concerned About Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Historical Volatility?
  9. Pacira to Report Second Quarter 2019 Financial Results on Thursday August 8, 2019
  10. DRRX: Favorable FDA Decision on POSIMIR Would Likely Mean Significant Upside to Our Model
  11. Pacira Gets EMA Acceptance for Pain Management Drug Exparel
  12. New Retrospective Analysis Shows EXPAREL Associated with Significantly Less Opioid Use Following Third Molar Extraction
  13. Pacira BioSciences Announces Validation of EXPAREL Marketing Authorization Application from European Medicines Agency
  14. Is Pacira BioSciences, Inc. (NASDAQ:PCRX) Trading At A 36% Discount?
  15. JAZZ or PCRX: Which Is the Better Value Stock Right Now?
  16. Pacira BioSciences Appoints Former Johnson & Johnson Executive, Max Reinhardt, as President
  17. See what the IHS Markit Score report has to say about Pacira Biosciences Inc.
  18. Edited Transcript of PCRX earnings conference call or presentation 2-May-19 12:30pm GMT